FDA Selects EMD to Present at Psychedelic Medicines Hearing

Key points

• Emyria invited to present at FDA's psychedelic medicines hearing
• Presentation will cover provider training, patient safety, access, and data
• Opportunity to showcase Australian clinical experience to U.S. regulators
• Potential to expand into the U.S. healthcare market

Full summary

Emyria Limited, a leader in innovative mental health treatments, has been selected by the U.S. Food and Drug Administration (FDA) to deliver in-person remarks at a public hearing on the future therapeutic use of psychedelic drugs. The hearing, scheduled for September 14, 2026, at the FDA's White Oak Campus in Maryland, will focus on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. Emyria's selection provides a unique opportunity to contribute real-world treatment experience from Australia to a U.S. federal discussion on psychedelic medicines, covering areas such as provider training, patient safety, access, and data collection.